Guardant's lab will make Guardant360 available to doctors and their patients in the region to help identify patients eligible for molecularly targeted drugs.
Investigators, led by Hong Kong researcher and Grail collaborator Dennis Lo, described a cancer detection strategy using cleavage patterns in circulating DNA molecules.
The decision, issued by Medicare Administrative Contractor Palmetto GBA, is effective Dec. 10 and provides coverage of the test for about 25,000 Medicare patients.
As one of six grantee projects, investigators from Yale, Harvard, and Rice University are partnering with Microsoft to bring forward a combined technique for the early detection of NSCLC.
The platform uses a gravity-based method to capture and isolate up to 100,000 individual cells per run, while maintaining viability and structural integrity.
In a conference call to discuss Q3 earnings, CEO Francis deSouza discussed NIPT, oncology, population sequencing, and consumer genomics as potential growth drivers.
The company has not released data on its method, but describes a circulating tumor DNA approach that has similarities to what other firms are pursuing.
The firm plans to conduct a prospective trial of a pan cancer assay and aims to bring another assay focused on colorectal cancer through FDA clearance.
The move will gain PFM a Houston lab, as well as ApoCell's proprietary ApoStream liquid biopsy technology for isolation and capture of circulating tumor cells.
Investigators developed a droplet digital PCR assay targeting driver mutations and found that changes in circulating DNA were correlated with response to radiation.
The study supports the use of liquid biopsy tests to guide treatment decisions, especially in patients who can't be biopsied, or don't have enough tissue available for standard testing.
In PLOS this week: MYRF variant linked to congenital diaphragmatic hernia, analysis of the "dragon's blood" red resin produced by traditional medicine plants, and more.
